Clinical Trial Update: Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of GLPG0634 (filgotinib) in methotrexate-refractory active rheumatoid arthritis has completed, reporting results from the dose-rangin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GLPG0634 (filgotinib)

Snippet

Sponsor: Galapagos NV | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED